Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma (NASDAQ: LTRN) announced the filing of seven global patent applications for a new DNA-damaging agent, LP-284, with demonstrated anticancer properties. LP-284, a preclinical small molecule candidate, shows promise in various cancer indications by inhibiting DNA damage and repair mechanisms. The distinct characteristics of LP-284, as a stereoisomer of LP-184, may enhance its therapeutic potential and integration into Lantern's portfolio. This strategic move reflects Lantern's ongoing commitment to advancing targeted oncology therapies through its RADR® A.I. platform.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced that CEO Panna Sharma will be featured in an interview on The RedChip Money Report on Bloomberg TV on March 13, 2021, at 7 p.m. local time. The discussion will cover the company's development pipeline, including its new Antibody Drug Conjugate program and collaborations with cancer centers. Lantern is advancing its genomically-targeted cancer therapeutics through its proprietary RADR® A.I. platform, aiming to improve patient outcomes.
Lantern Pharma (NASDAQ: LTRN) announced its fourth quarter and fiscal year 2020 results, highlighting key operational achievements and financial metrics. The company completed a public offering raising $69.0 million in January 2021, strengthening its balance sheet. Lantern's cash and equivalents stood at $19.2 million at year-end. R&D and G&A expenses increased significantly due to expansions in research activities and public company expenses. Notably, net losses were $2.9 million for Q4 2020, up from $0.7 million in Q4 2019. The company anticipates a transformational 2021 with advancements in drug trials and collaborations.
Lantern Pharma (NASDAQ: LTRN) will host a conference call on March 10, 2021, at 4:00 p.m. ET to discuss its fourth quarter and fiscal year 2020 results. The conference will be led by Panna Sharma, CEO, along with the management team. Participants can join via phone or online at their official webcast link. A replay will be available until April 10, 2021. Lantern Pharma utilizes its RADR® A.I. platform for drug discovery and aims to enhance patient outcomes through precision therapeutics, focusing on unmet clinical needs in oncology.
Lantern Pharma (LTRN) has successfully closed a public offering of 4,928,571 shares at $14.00 each, raising gross proceeds of approximately $69 million. The offering included 642,856 shares from the underwriter's over-allotment option. This follows the effective registration statement filed on January 14, 2021. Lantern focuses on transforming cancer drug development through its proprietary RADR® AI platform, targeting precision therapeutics for oncology. The funds raised may support the advancement of its clinical pipeline addressing unmet patient needs.
Lantern Pharma (LTRN) has announced a public offering of 4,285,715 shares at $14.00 per share, aiming for gross proceeds of $60 million, set to close on January 20, 2021. The underwriters hold a 45-day option to purchase an additional 642,856 shares to cover over-allotments. The offering is managed by ThinkEquity and Colliers Securities. A registration statement was filed with the SEC and is effective as of January 14, 2021. Lantern Pharma focuses on repurposing cancer therapies using AI and has two clinical-stage and one preclinical drug in its pipeline.
Lantern Pharma (LTRN) has announced the initiation of an Antibody Drug Conjugate (ADC) program, collaborating with Califia Pharma for development and evaluation. This program aims to target solid tumors and blood cancers using innovative linker technologies and DNA damage compounds, LP-100 and LP-184. Industry analysts project the global ADC market could exceed $10 billion by 2026. Lantern will leverage its RADR® A.I. platform to identify optimal cancer types and biomarker signatures for targeted therapies, intending to launch clinical trials by 2022.
Lantern Pharma (LTRN) announced a collaboration with Johns Hopkins to advance its LP-184 drug candidate for glioblastoma multiforme (GBM). This partnership aims to develop targeted applications for LP-184, utilizing patient-derived cancer models to enhance the understanding of its mechanisms. CEO Panna Sharma emphasized the significance of this collaboration in harnessing advanced methodologies and expanding the RADR® A.I. platform's data capabilities. The initiative seeks to improve patient outcomes in GBM, which has a grim five-year survival rate of only 5.5%.
Lantern Pharma (LTRN) announced promising preclinical data showing that its drug candidate, LP-184, can effectively cross the blood-brain barrier, crucial for treating Glioblastoma Multiforme (GBM). GBM, the most aggressive brain cancer, has a median survival of only 15 months and no current cure. The global GBM market is expected to reach $3.3 billion by 2024. Unlike standard treatments, LP-184 has a different mechanism of action, making it a potential option for patients resistant to current therapies. Lantern aims to accelerate clinical trials for LP-184, targeting a broader spectrum of CNS cancers.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO, Panna Sharma, will participate in three virtual investor events this December. Notable events include the Diamond Equity Research Emerging Growth Invitational on December 1, 2020, and the Benzinga Global Small Cap Conference on December 9, 2020. Lantern Pharma utilizes its proprietary RADR® A.I. platform for oncology drug development, focusing on drug repurposing and improving patient outcomes by identifying suitable candidates based on genomic profiles.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
